User login
VIENNA – Given atezolizumab’s success over chemotherapy in the recent POPLAR trial, is it time to think of immunotherapy as a first-line option for relapsed non–small-cell lung cancer?
“Several data sets, including POPLAR but also with other immune checkpoint inhibitors, have now shown that immunotherapy outcomes are superior to standard chemotherapy outcomes in the relapsed treatment of non–small-cell lung cancer,” noted POPLAR study author Dr. Johan Vansteenkiste of University Hospitals Leuven, Belgium.
In an interview at the European Cancer Congress 2015, Dr. Vansteenkiste discussed the potential for immunotherapy to become a standard relapse treatment for NSCLC, either alone or as combination treatment with chemotherapy.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @pwendl
VIENNA – Given atezolizumab’s success over chemotherapy in the recent POPLAR trial, is it time to think of immunotherapy as a first-line option for relapsed non–small-cell lung cancer?
“Several data sets, including POPLAR but also with other immune checkpoint inhibitors, have now shown that immunotherapy outcomes are superior to standard chemotherapy outcomes in the relapsed treatment of non–small-cell lung cancer,” noted POPLAR study author Dr. Johan Vansteenkiste of University Hospitals Leuven, Belgium.
In an interview at the European Cancer Congress 2015, Dr. Vansteenkiste discussed the potential for immunotherapy to become a standard relapse treatment for NSCLC, either alone or as combination treatment with chemotherapy.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @pwendl
VIENNA – Given atezolizumab’s success over chemotherapy in the recent POPLAR trial, is it time to think of immunotherapy as a first-line option for relapsed non–small-cell lung cancer?
“Several data sets, including POPLAR but also with other immune checkpoint inhibitors, have now shown that immunotherapy outcomes are superior to standard chemotherapy outcomes in the relapsed treatment of non–small-cell lung cancer,” noted POPLAR study author Dr. Johan Vansteenkiste of University Hospitals Leuven, Belgium.
In an interview at the European Cancer Congress 2015, Dr. Vansteenkiste discussed the potential for immunotherapy to become a standard relapse treatment for NSCLC, either alone or as combination treatment with chemotherapy.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @pwendl
EXPERT ANALYSIS FROM THE EUROPEAN CANCER CONGRESS 2015
